Company Interview / Ryan's buy-case for beaten-up CSL

Key Points:

Lim sees CSL (ASX:CSL) as undervalued with upside towards $140 Cost-out programme and operational execution viewed as stronger than sentiment implies Vifor issues traced to incentives and accounting focus on NPATA, not acquisition efficiency CSL (ASX:CSL) valuation and whether current levels represent opportunity or value trap

Ryan Lim from Alpha Insights sets out a contrarian but constructive view on CSL (ASX:CSL), arguing the recent share price slump and series of downgrades stem from a single issue: the Vifor acquisition and how it is accounted for. Lim states that his valuation work has long pointed to fair value of about $120–$140 per share, even when the stock traded above $200, and he now sees the market reaction as excessive with much of the bad news already reflected in the price.

Lim notes CSL has, in his view, executed well on its transformation and cost-out programme, estimating around 60% of targeted savings already achieved, with the remainder likely to support earnings over the next 6–12 months. He adds that near-term catalysts could include appointment of a new CEO, potential weakening of the AUD against the USD and any wobble in credit markets, all of which he expects to be supportive for CSL’s earnings and rating.

Looking further out, Lim acknowledges structural risks from emerging competitors to plasma products over a five-year horizon, but continues to see CSL as a high-quality global infrastructure-like business with entrenched distribution, relationships and technology, rather than a single-product pharmaceutical story.